Komori
Sekisui Chemical (4204) · InitiativeFirst stated

Expansion of Reagent Sales Following Public Funding for Expanded Newborn Screening Tests

First written in FY2025-H1. . Latest entry: FY2025-H1.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Expansion of Reagent Sales Driven by Public Funding for Expanded Newborn ScreeningA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2025-H1First statedAnnual report

    「医療事業では、医薬品原料の受託製造における主力製品の生産調整の影響があったが、創薬支援の受託試験が堅調に推移したことに加え、拡大新生児マススクリーニング検査の公費化を受け試薬の販売などが拡大したことにより、売上高は前年同期を上回った。」

    拡大新生児マススクリーニング検査の公費化を受け、試薬販売などが拡大したと初めて記載された。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Sekisui Chemical's next results are scheduled for 2026-10-30. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.